Supplemental Material and Methods, Table 1, and Figures 1-7 from Systematic Screening Identifies Dual PI3K and Mtor Inhibition As a Conserved Therapeutic Vulnerability in Osteosarcoma

Supplemental Material and Methods, Table 1, and Figures 1-7. Supplemental Table 1 - Primer Sequences used for qPCR. Supplemental Figure 1 - Suppressors of doxorubicin induced cell death from siRNA screen. Supplemental Figure 2 - Response to Spliceostatin A treatment. Supplemental Figure 3 - Dose response of curves of murine and human OS cells to dual PI3K/mTOR inhibitors. Supplemental Figure 4 - siRNA against PI3K subunits and mTOR complex components Supplemental Figure 5 - BYL719 and Everolimus Synergy Matrix Supplemental Figure 6 - BYL719 and Everolimus treatment of primary murine osteoblasts. Supplemental Figure 7. GSK2126458 treatment reduces OS tumour proliferation in vivo.